Anil Lalwani | VP CMC and Quality
Anil Lalwani has over 25 years of technical, CMC-centric industry experience with a focus on phase-appropriate products development that meets or exceeds contemporary regulatory expectations. He leveraged his industry experience in academia to help translational (bench-to-clinic) programs with CMC, QA, and FDA engagement for autologous cell therapy and implantable neuromodulation devices for spinal cord injury and pain, a gene therapy (AAV2) for retinal dystrophy (LHON), and allogeneic bone marrow and umbilical cord-derived mesenchymal stem cell products for neurological diseases.
Anil’s recent regulatory CMC experiences at Allergan (now AbbVie) on a CRISPR/Cas9 gene therapy program, his track record, and his passion for helping unmet need patients adds depth and breadth to Nanoscope’s growing team and portfolio.
Anil holds a BSc in Mechanical Engineering from Rutgers University, an MSc in Biotechnology Engineering from the University of Pennsylvania, and an MBA in Health Care from the University of Miami.
